MedPath

Beclomethasone Dipropionate

Generic Name
Beclomethasone Dipropionate
Brand Names
Alanase, Beconase, Propaderm, Qnasl, Qvar, Rivanase AQ
Drug Type
Small Molecule
Chemical Formula
C28H37ClO7
CAS Number
5534-09-8
Unique Ingredient Identifier
5B307S63B2
Background

Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to dexamethasone. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Beclomethasone dipropionate itself posesses weak glucocorticoid receptor binding affinity and is rapidly converted into 17-BMP upon administration. Formulations for oral inhalation, intranasal, and topical use are available for beclomethasone dipropionate. Beclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray. Due to its anti-inflammatory, antipruritic, and anti-allergy properties, beclomethasone dipropionate is used in various inflammatory conditions, such as asthma, allergic rhinitis, and dermatoses to reduce symptoms. When inhaled, it is proposed that beclomethasone dipropionate remains active locally in the lung without causing significant side effects associated with systemic corticosteroids. Compared to earlier corticosteroids such as dexamethasone and prednisolone, beclomethasone dipropionate is reported to be less irritating to the nasal mucosa with a longer duration of action when administered intranasally.

Indication

糖皮质激素类药。主要用于持续性哮喘的长期治疗。按照支气管哮喘严重程度分级标准,在轻度持续(2级以上)即可使用吸入糖皮质激素治疗;外用适用于对糖皮质激素外用有效的各种非感染性炎症性皮肤病,如亚急性和慢性湿疹、脂溢性皮炎、接触性皮炎、特应性皮炎、局限性神经性皮炎、寻常型银屑病、盘状红斑狼疮、扁平苔癣等。亦可用于常年性变应性鼻炎和季节性变应性鼻炎及血管收缩性鼻炎;亦用于鼻息肉切除术后,预防息肉的再生。

Associated Conditions
Asthma, Bacterial Sinusitis, Chronic Sinusitis, Dermatosis, Fungal skin infection, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Recurrent nasal polyps

Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: FlF/VI + Tiotropium
First Posted Date
2015-06-10
Last Posted Date
2021-10-29
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
1479
Registration Number
NCT02467452
Locations
🇭🇺

Erzsebet Gondozohaz, Godollo, Hungary

The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms

Phase 4
Completed
Conditions
Asthma
Interventions
First Posted Date
2014-11-19
Last Posted Date
2017-04-25
Lead Sponsor
Research in Real-Life Ltd
Target Recruit Count
360
Registration Number
NCT02294279
Locations
🇬🇧

Research in Real Life Ltd, Oakington, Cambridgeshire, United Kingdom

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: FS MDPI
Drug: Fp MDPI
Drug: Placebo MDPI
Drug: albuterol/salbutamol
First Posted Date
2014-05-15
Last Posted Date
2021-11-12
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
787
Registration Number
NCT02139644
Locations
🇺🇸

Teva Investigational Site 12584, Longmont, Colorado, United States

🇺🇸

Teva Investigational Site 12379, Centennial, Colorado, United States

🇺🇸

Teva Investigational Site 12586, Fountain Valley, California, United States

and more 137 locations

Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis

Phase 2
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: placebo
First Posted Date
2014-01-29
Last Posted Date
2019-07-15
Lead Sponsor
Hull University Teaching Hospitals NHS Trust
Target Recruit Count
20
Registration Number
NCT02048644
Locations
🇬🇧

Respiratory Medicine Clinical trials Unit, Cottingham, East Yorkshire, United Kingdom

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Placebo
Drug: Albuterol/salbutamol
First Posted Date
2014-01-09
Last Posted Date
2021-11-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
1113
Registration Number
NCT02031640
Locations
🇺🇸

Teva Investigational Site 10861, Los Angeles, California, United States

🇺🇸

Teva Investigational Site 10832, Baltimore, Maryland, United States

🇺🇸

Teva Investigational Site 10866, Seattle, Washington, United States

and more 128 locations

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease

Phase 3
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: BDP/FF + Tiotropium
First Posted Date
2013-07-30
Last Posted Date
2021-10-29
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
3686
Registration Number
NCT01911364
Locations
🇮🇹

Azienda Ospedaliera Perugia, Perugia, Italy

🇩🇪

Institut für klinische Forschung, Hessen, Germany

🇭🇺

Csongrád Megyei Mellkasi Betegségek Szakkórháza, Szeged, Hungary

Targeted Small Airways Therapy in Persistent Asthma

Phase 4
Completed
Conditions
Asthma
Interventions
First Posted Date
2013-07-09
Last Posted Date
2019-09-09
Lead Sponsor
University of Dundee
Target Recruit Count
26
Registration Number
NCT01894048
Locations
🇬🇧

Brian Lipworth, Dundee, United Kingdom

Allergic Rhinitis Changes the Sinus Microbiome

Phase 4
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
Drug: Placebo nasal spray
First Posted Date
2013-05-13
Last Posted Date
2020-10-09
Lead Sponsor
University of Chicago
Target Recruit Count
39
Registration Number
NCT01852513
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

Phase 3
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: Placebo
First Posted Date
2012-10-02
Last Posted Date
2015-10-08
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
99
Registration Number
NCT01697956
Locations
🇺🇸

Teva Investigational Site 10305, Long Beach, California, United States

🇺🇸

Teva Investigational Site 10304, Stockbridge, Georgia, United States

🇺🇸

Teva Investigational Site 10302, Normal, Pennsylvania, United States

and more 3 locations

Beta Blocker Therapy in Mild to Moderate Asthmatics

Phase 2
Completed
Conditions
Asthma
Interventions
First Posted Date
2012-03-06
Last Posted Date
2018-03-30
Lead Sponsor
University of Dundee
Target Recruit Count
16
Registration Number
NCT01544634
Locations
🇬🇧

Asthma and Allergy Research Group, University of Dundee, Dundee, Scotland, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath